News headlines about Egalet (NASDAQ:EGLT) have trended somewhat positive recently, according to Accern Sentiment. Accern rates the sentiment of press coverage by reviewing more than twenty million blog and news sources in real time. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Egalet earned a coverage optimism score of 0.14 on Accern’s scale. Accern also gave media stories about the specialty pharmaceutical company an impact score of 48.5410458117869 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the stock’s share price in the immediate future.
These are some of the media stories that may have effected Accern’s scoring:
- Momentum Stocks: in Focus (RSI – A Momentum Oscillator) RSI Alert Egalet Corporation (NASDAQ:EGLT), Civeo … (thestreetpoint.com)
- Have a look on Price-Earnings Ratio->These ratio reflects investors’ assessments of those future earnings Egalet … (thestreetpoint.com)
- Sizzling Stocks Update: Egalet Corporation (NASDAQ:EGLT), SandRidge Permian Trust (NYSE:PER), Cellect … (journalfinance.net)
- Return on Equity (ROE) in the Spotlight: Egalet Corporation (NASDAQ:EGLT), Devon Energy Corporation (NYSE:DVN … (stocksnewspoint.com)
- Comprehensive Stock Analysis: Egalet Corporation (EGLT) (topdesertsafari.com)
A number of brokerages have recently commented on EGLT. Cantor Fitzgerald cut shares of Egalet from an “overweight” rating to a “neutral” rating in a research report on Tuesday, May 22nd. ValuEngine upgraded shares of Egalet from a “sell” rating to a “hold” rating in a research report on Saturday, June 2nd. Finally, JMP Securities reduced their target price on shares of Egalet from $4.00 to $1.50 and set a “market outperform” rating for the company in a research report on Thursday, August 9th. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Egalet has a consensus rating of “Hold” and an average target price of $1.67.
Shares of NASDAQ EGLT traded down $0.01 during mid-day trading on Friday, reaching $0.30. The company’s stock had a trading volume of 293,440 shares, compared to its average volume of 808,896. The stock has a market capitalization of $20.73 million, a price-to-earnings ratio of -0.12 and a beta of 0.37. The company has a quick ratio of 1.32, a current ratio of 1.37 and a debt-to-equity ratio of -1.81. Egalet has a 1-year low of $0.26 and a 1-year high of $1.59.
Egalet (NASDAQ:EGLT) last issued its earnings results on Wednesday, August 8th. The specialty pharmaceutical company reported ($0.22) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.06. The business had revenue of $7.44 million during the quarter, compared to analyst estimates of $8.64 million. equities research analysts expect that Egalet will post -0.93 EPS for the current year.
Egalet Company Profile
Egalet Corporation, a specialty pharmaceutical company, develops, manufactures, and commercializes treatments for patients with pain and other conditions. It has licensed three approved pain products, such as SPRIX Nasal Spray, a non-steroidal anti-inflammatory drug indicated in adult patients for the short-term management of moderate to moderately severe pain that requires analgesia at the opioid level; OXAYDO, an immediate-release oxycodone product designed to discourage abuse via snorting for the management of acute and chronic pain severe enough to require an opioid analgesic, and for which alternative treatments are inadequate; and ARYMO ER, an extended-release (ER) morphine product formulated with abuse-deterrent (AD) properties for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment and for which alternative treatment options are inadequate.
Receive News & Ratings for Egalet Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Egalet and related companies with MarketBeat.com's FREE daily email newsletter.